Medtronic Seals FDA Panel Endorsement With InFuse Bone Growth Product
This article was originally published in The Gray Sheet
Executive Summary
Preclinical studies of the effects of recombinant human bone morphogenetic protein-2 (rhBMP-2) on tumorogenicity, dosing and antibody response during pregnancy should be conducted by Medtronic/Sofamor Danek, FDA's Orthopedic & Rehabilitation Devices Panel recommended Jan. 10
You may also be interested in...
Spinal Fusion Surgery Rebuked In NEJM “Sounding Board” Article
FDA should provide closer scrutiny of spinal implants and their use for unapproved indications, according to scientists critical of emerging technologies for spinal fusion surgery
Spinal Fusion Surgery Rebuked In NEJM “Sounding Board” Article
FDA should provide closer scrutiny of spinal implants and their use for unapproved indications, according to scientists critical of emerging technologies for spinal fusion surgery
OrthoLogic Chrysalin Phase III Fracture Repair NDA Study To Begin This Fall
OrthoLogic believes that pursuing approval of its orthobiologic product Chrysalin through a new drug application (NDA) will enable fuller discussion of the product's method of action in marketing materials